Bermúdez BPE, Sánchez RA, Turrent CA, Amigo CMC

Language: Spanish
References: 11
Page: 177-181
PDF size: 216.47 Kb.

ABSTRACT

Background: There is insufficient information in the medical literature that outlines the assessment of chronic damage in patients with antiphospholipid syndrome (APS) with the instrument Damage Index in Antiphospholipid Syndrome (DIAPS). Objective: To assess, using the DIAPS scale, the chronic damage in outpatients with antiphospholipid syndrome. Methods: We conducted a cross-sectional, prospective study in outpatients with APS during the period from January 2014 to January 2015. We included demographic, clinical and laboratory data. All patients were assessed with the DIAPS instrument. Results: Twenty-nine patients aged 42.6 ± 16.6 years were included; 86.2% females; 6.9% with a catastrophic course. The DIAPS instrument scored with a median of two (interquartile range, one to five). Variables associated with higher scores were acenocoumarin [median = 3 (interquartile range 1-7) versus 1 (interquartile range 0-3), p = 0.035] and arterial thrombosis [median = 3 (interquartile range 1-7) versus 2.5 (interquartile range 1-5), p = 0.07]. We found no associations with the clinical course, serology patterns and DIAPS score. Conclusions: Most of our patients rated low scores in the DIAPS instrument. Variables related to higher scores were acenocoumarin and arterial thrombosis; however the latter did not reach statistical signifi-cance. Longitudinal studies should evaluate the serial measurements of the DIAPS score.

REFERENCES

1. Girón-González JA, García del Río E, Rodríguez C, Rodríguez-Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004; 31 (8): 1560-1567.

2. Aguiar, CL, Erkan D. Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease. Ther Adv Musculoeskel Dis. 2013; 5 (6): 305-314.

3. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol. 2002; 29 (12): 2531-2536.

4. Grika EP, Ziakas PD, Zintzaras E, Moutsopoulos HM, Vlachoyiannopoulos PG. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol. 2012; 39 (3): 516-523.

5. Mok C, Chan P, Ho L, Yu K, To C. Prevalence of the antiphospholipid syndrome and its effect on survival in 679 Chinese patients with systemic lupus erythematosus. Medicine. 2013; 92 (4): 217-222.

6. Humphrey L, Heron L, Pilling C, Holloway L, Højbjerre L, Strandberg-Larsen M et al. Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a content validity and psychometric performance review. Value in Health. 2013; 16 (7): A600.1.

7. Holloway L, Humphrey L, Heron L, Pilling C, Kitchen H, Højbjerre L et al. Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance. Health Qual Life Outcomes. 2014; 12: 116.

8. Amigo MC, Goycochea-Robles MV, Espinosa-Cuervo G, Medina G, Barragán-Garfias JA, Vargas A et al. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus. 2015; 24 (9): 927-934.

9. Zuily S, Rat A, Regnault V, Kaminsky P, Mismetti P, Ninet J et al. Impairment of quality of life in patients with antiphospholipid syndrome. Lupus. 2015; 24 (11): 1161-1168.

10. Ruiz-Irastorza G, Egurbide M, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med. 2004; 164 (1): 77-82.

11. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996; 39 (3): 363-369.